Cboe Global Markets Reports Trading Volume for September 2026

Cboe reported strong September and Q3 derivatives activity: September index-options ADV rose 22.3% year over year to 6.422 million contracts, while quarterly SPX 0DTE ADV set a record at 3.2 million contracts and quarterly multi-listed options ADV reached 15.3 million. The company also issued preliminary Q3 revenue-per-contract/net-capture guidance, including total options RPC of $0.307; figures may change before final reporting. Activity was mixed across other businesses, with September U.S. on-exchange equities matched-share ADV down 14.7% year over year.

Analysis

The read-through is positive for Cboe’s differentiated index-options franchise, not a uniform exchange-volume upswing. Record SPX/XSP 0DTE activity and strength in Russell options can support monetization of proprietary products, while stable index-options capture suggests the surge is not obviously being bought through lower fees. The counterweight is weaker U.S. on-exchange equities and a declining multi-listed-options capture rate: more contracts do not automatically translate into proportionate earnings growth. FX volume growth alongside lower capture reinforces the need to judge the quarter on revenue mix and net capture, not ADV headlines.

The near-term catalyst is final Q3 results: verify options transaction revenue, product mix, and whether preliminary capture holds. The one-month reporting lag and rolling-average methodology limit the precision of this release as an earnings estimate. Over 6–18 months, continued 0DTE adoption favors Cboe’s index franchise, but concentrates the bull case in products exposed to shifts in volatility, customer behavior, and regulatory scrutiny. A sharp decline in volatility could reduce activity; a fee or product challenge to proprietary index options would undermine the differentiated thesis. The contrarian risk is that investors may treat record volumes as durable earnings acceleration even as multi-listed capture and cash-equity activity signal pressure elsewhere. No reliable valuation or consensus data here supports a price target or an aggressive outright trade.

Key Decisions for Investors

• Maintain a modest positive bias to CBOE, but prefer adding on weakness rather than chasing the volume release; the earnings case depends more on proprietary index-option monetization than on broad market activity.
• At Q3 results, test the thesis against final options revenue and RPC by product, plus the contribution from SPX/XSP and 0DTE. If elevated index volumes fail to lift transaction revenue or index capture weakens materially, reduce the positive bias.
• Track multi-listed-options capture and U.S. on-exchange equity activity as downside alerts: persistent deterioration would indicate that headline ADV is masking fee/mix pressure.
• Watch for regulatory scrutiny or exchange/customer changes affecting 0DTE and proprietary index products. A sustained drop in those volumes or a challenge to Cboe’s product exclusivity would falsify the structural-growth case.